Order Article Reprints

Perri F, Longo F, Fusco R, D’Alessio V, Aversa C, Pavone E, Pontone M, Marciano ML, Villano S, Franco P, et al. Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210. Cancers. 2021; 13(14):3412. https://doi.org/10.3390/cancers13143412

Perri, Francesco, Francesco Longo, Roberta Fusco, Valeria D’Alessio, Corrado Aversa, Ettore Pavone, Monica Pontone, Maria Luisa Marciano, Salvatore Villano, Pierluigi Franco, and et al. 2021. "Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210" Cancers 13, no. 14: 3412. https://doi.org/10.3390/cancers13143412

Perri, F., Longo, F., Fusco, R., D’Alessio, V., Aversa, C., Pavone, E., Pontone, M., Marciano, M. L., Villano, S., Franco, P., Togo, G., De Fazio, G. R., Ordano, D., Maglitto, F., Salzano, G., Maglione, M. G., Guida, A., & Ionna, F. (2021). Addendum: Perri et al. Electrochemotherapy as a First Line Treatment in Recurrent Squamous Cell Carcinoma of the Oral Cavity and Oropharynx PDL-1 Negative and/or with Evident Contraindication to Immunotherapy: A Randomized Multicenter Controlled Trial. Cancers 2021, 13, 2210. Cancers, 13(14), 3412. https://doi.org/10.3390/cancers13143412